An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its ...

Former President Joe Biden's prostate cancer diagnosis has sparked an important discussion on screenings. It is a warning for ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sharon Choi discussing comprehensive genomic profiling of Black and non-Hispanic White men with prostate cancer. Racial ...

Guidelines created by a multi-disciplinary panel of specialists ... they called out the need for routine genetic testing of patients with advanced prostate cancer and emphatically called out ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

More recently, they’ve discovered some of these same genes can raise a man’s risk for prostate cancer, too. If you carry a gene that could be involved in the development of prostate cancer ...

In addition to the MRD oral abstract, additional research highlights include: “We have an exciting, diverse, and sizable slate of oncology results being presented at ASCO this year, where each ...

Standard medical practice is to not test men who have a life expectancy of less than 10 years for prostate cancer.